The In Vivo and In Vitro Assessment of Pyocins in Treating Pseudomonas aeruginosa Infections

Pseudomonas aeruginosa can cause several life-threatening infections among immunocompromised patients (e.g., cystic fibrosis) due to its ability to adapt and develop resistance to several antibiotics. In recent years, P. aeruginosa infections has become difficult to treat using conventional antibiot...

Descripción completa

Detalles Bibliográficos
Autores principales: Alqahtani, Abdulaziz, Kopel, Jonathan, Hamood, Abdul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598984/
https://www.ncbi.nlm.nih.gov/pubmed/36290026
http://dx.doi.org/10.3390/antibiotics11101366
_version_ 1784816483536207872
author Alqahtani, Abdulaziz
Kopel, Jonathan
Hamood, Abdul
author_facet Alqahtani, Abdulaziz
Kopel, Jonathan
Hamood, Abdul
author_sort Alqahtani, Abdulaziz
collection PubMed
description Pseudomonas aeruginosa can cause several life-threatening infections among immunocompromised patients (e.g., cystic fibrosis) due to its ability to adapt and develop resistance to several antibiotics. In recent years, P. aeruginosa infections has become difficult to treat using conventional antibiotics due to the increase multidrug-resistant P. aeruginosa strains. Therefore, there is a growing interest to develop novel treatments against antibiotic-resistance P. aeruginosa strains. One novel method includes the application of antimicrobial peptides secreted by P. aeruginosa strains, known as pyocins. In this review, we will discuss the structure, function, and use of pyocins in the pathogenesis and treatment of P. aeruginosa infection.
format Online
Article
Text
id pubmed-9598984
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95989842022-10-27 The In Vivo and In Vitro Assessment of Pyocins in Treating Pseudomonas aeruginosa Infections Alqahtani, Abdulaziz Kopel, Jonathan Hamood, Abdul Antibiotics (Basel) Review Pseudomonas aeruginosa can cause several life-threatening infections among immunocompromised patients (e.g., cystic fibrosis) due to its ability to adapt and develop resistance to several antibiotics. In recent years, P. aeruginosa infections has become difficult to treat using conventional antibiotics due to the increase multidrug-resistant P. aeruginosa strains. Therefore, there is a growing interest to develop novel treatments against antibiotic-resistance P. aeruginosa strains. One novel method includes the application of antimicrobial peptides secreted by P. aeruginosa strains, known as pyocins. In this review, we will discuss the structure, function, and use of pyocins in the pathogenesis and treatment of P. aeruginosa infection. MDPI 2022-10-07 /pmc/articles/PMC9598984/ /pubmed/36290026 http://dx.doi.org/10.3390/antibiotics11101366 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Alqahtani, Abdulaziz
Kopel, Jonathan
Hamood, Abdul
The In Vivo and In Vitro Assessment of Pyocins in Treating Pseudomonas aeruginosa Infections
title The In Vivo and In Vitro Assessment of Pyocins in Treating Pseudomonas aeruginosa Infections
title_full The In Vivo and In Vitro Assessment of Pyocins in Treating Pseudomonas aeruginosa Infections
title_fullStr The In Vivo and In Vitro Assessment of Pyocins in Treating Pseudomonas aeruginosa Infections
title_full_unstemmed The In Vivo and In Vitro Assessment of Pyocins in Treating Pseudomonas aeruginosa Infections
title_short The In Vivo and In Vitro Assessment of Pyocins in Treating Pseudomonas aeruginosa Infections
title_sort in vivo and in vitro assessment of pyocins in treating pseudomonas aeruginosa infections
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598984/
https://www.ncbi.nlm.nih.gov/pubmed/36290026
http://dx.doi.org/10.3390/antibiotics11101366
work_keys_str_mv AT alqahtaniabdulaziz theinvivoandinvitroassessmentofpyocinsintreatingpseudomonasaeruginosainfections
AT kopeljonathan theinvivoandinvitroassessmentofpyocinsintreatingpseudomonasaeruginosainfections
AT hamoodabdul theinvivoandinvitroassessmentofpyocinsintreatingpseudomonasaeruginosainfections
AT alqahtaniabdulaziz invivoandinvitroassessmentofpyocinsintreatingpseudomonasaeruginosainfections
AT kopeljonathan invivoandinvitroassessmentofpyocinsintreatingpseudomonasaeruginosainfections
AT hamoodabdul invivoandinvitroassessmentofpyocinsintreatingpseudomonasaeruginosainfections

Ejemplares similares